Exelixis Q2 Miss and Lowered 2026 Outlook Trigger Investigation and After-Hours Drop

What happened

Exelixis reported Q2 2026 revenue of approximately $628.7 million, missing consensus estimates, and simultaneously lowered and narrowed its full-year 2026 revenue outlook. The announcement caused shares to drop in after-hours trading, and law firm Levi & Korsinsky announced an investor investigation into the company. The revenue shortfall and reduced guidance directly contradict the prior base-case expectation that Cabometyx would sustain mid-teens growth and meet the previously guided range of $2.325–2.425 billion in net product revenue for 2026. This negative catalyst amplifies existing concerns in the master report regarding heavy single-product concentration, impending patent cliffs, and pricing pressures that were already weighing on the margin of safety. While the company remains profitable with strong cash flows, the guidance reduction signals that growth is decelerating faster than modeled, increasing downside risk relative to the prior WAIT rating.

Implication

Investors should reassess the investment thesis given the guidance reduction, as it weakens the base-case assumption of sustained Cabometyx growth. The stock's current valuation near $44 with a P/E of ~17x now appears less justified if revenue growth is slowing, especially with patent expirations looming in 2026–2027 and active generic challenges. The lowered outlook may also pressure management's ability to fund the planned R&D ramp and share buybacks without straining the balance sheet. However, Exelixis still has a strong cash position (~$1.57B) and zanzalintinib remains an unmodeled upside, so a severe de-rating may be premature. A more prudent approach is to wait for evidence that the revenue miss is transient rather than structural, or for the stock to decline toward the prior attractive entry of $38, before adding positions.

Thesis delta

The thesis shifts from a WAIT based on balanced risk/reward to a more cautious WAIT with reduced conviction, as the Q2 revenue miss and lowered guidance undermine the base-case growth trajectory. The previous expectation that Cabometyx would meet or exceed guidance for two consecutive quarters as a condition for increasing conviction is now unlikely in the near term. Consequently, the probability of the bear scenario (revenue slowdown and stagnant net prices) rises, while the base-case implied value of $48 may need to be marked down if trends persist.